Prediction of a novel prostate-specific antigen density cutoff value and use of transrectal ultrasound-guided prostate biopsy for diagnosis of prostate cancer in Thailand
DOI:
https://doi.org/10.52786/isu.a.42Keywords:
PSAD, prostate-specific antigen density, prostate cancer detectionAbstract
Objective: The measurement of prostate-specific antigen density (PSAD) is a noninvasive and inexpensive practice, which may improve the accurate diagno- sis of prostate cancer. The incidence of prostate cancer in Thailand is relatively low compared with that in Western countries. Therefore, a blanket adoption of the Western cutoff value (PSAD 0.15 ng/ml/cm3) is inapplicable and can lead to unnecessary biopsies. The aim of this study was to determine an optimal PSAD cutoff value for effective diagnosis in Thai men.
Materials and Methods: We retrospectively studied transrectal ultrasound-guided prostate biopsies from 542 men with intermediate PSA concentrations ranging from 4 to 10 ng/ml, carried out from January 2011 to January 2017. The area under the receiver operating characteristic curve (AuROC) was used to evaluate the efficacy of PSAD for the diagnosis of prostate cancer.
Results: In Thai men who had intermediate PSA concentrations, the AuROC was higher for PSAD in comparison to that of PSA (0.692 vs 0.544). The AuROC using the PSAD cutoff value = 0.20 ng/ml/cm3 was higher than that using the PSAD cutoff value = 0.15 ng/ml/cm3 (0.652 vs 0.626). The sensitivity, specificity, positive predictive value, and negative predictive values were 67.33%, 62.13%, 29.95%, and 89.15%, respectively.
Conclusion: PSAD improved the diagnosis of prostate cancer in Thai men with intermediate PSA concentrations. The optimal cutoff value was 0.20 ng/ml/cm3.
References
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
Lavallée LT, Binette A, Witiuk K, Cnossen S, Mallick R, Fergusson DA, et al. Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing. Mayo Clinic Proc 2016;91:17-22.
Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-21.
Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol 2007;51:659-64.
National Comprehensice Cancer Network [Inter- net]. Prostate Cancer Early Detection (Version 2.2019) [cited 2021 Jan 1]. Available from: https:// www.nccn.org/professionals/physician_gls/pdf/ prostate_detection.pdf.
Hospital-based cancer registry 2017. In: Services DoM, editor. Bangkok: Institute NC; 2017.
Andrew J, Stephenson EAK. Epidemiology, Etiology, and Prevention of Prostate Cancer. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier; 2020. p. 3458-77.
Sirisopana K, Sirisreetreerux P, Viseshsindh W, Kijvikai K, Kongcharoensombat W, Pacharatakul S, et al. Optimal prostate-specific antigen (PSA) cut-off value and transrectal ultrasound guided prostate biopsy in the diagnosis of prostate cancer in Ramathibodi Hospital: first study in South East Asia. J Med Assoc Thai 2019;102:52-5.
Akdas A, Tarcan T, Türkeri L, Cevik I, Biren T, Ilker Y. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ ml. Eur Urol 1996;29:189-92.
Rico L, Contreras P, Vitagliano G, Rios Pita H, Ameri C, Blas L. Value of prostate-specific antigen density in negative or equivocal lesions on multi-parametric magnetic resonance imaging. Turk J Urol 2020;46:367-72.
Faisal FA, Sundi D, Pierorazio PM, Ball MW, Hum- phreys EB, Han M, et al. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature. BJU Int 2014;114:e120-9.
Saema A, Kochakarn W, Lertsithichai P. PSA density and prostate cancer detection. J Med Assoc Thai 2012;95:661-6.
Gohji K, Nomi M, Egawa S, Morisue K, Takenaka A, Okamoto M, et al. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer 1997;79:1969-76.
Muangman V. Vasectomy: clinical aspects and reversibility. J Thai Assoc Volunt Steriliz 1979:79-83. 15. Rahardjo D, Kamil ST, Pakasi LS. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence. Gan To Kagaku Ryoho 2000;27:563-70.
Lin YR, Wei XH, Uhlman M, Lin XT, Wu SF, Diao PF, et al. PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1): a multicenter study. Asian J Androl 2015;17:503-7.
Matthews GJ, Motta J, Fracehia JA. The accuracy of transrectal ultrasound prostate volume estimation: clinical correlations. J Clin Ultrasound 1996;24:501-5.
Sajadi KP, Terris MK, Hamilton RJ, Cullen J, Amling CL, Kane CJ, et al. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. J Urol 2007;178:990-5.
Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 2006;68:352-6.
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
Filella X, Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729-39.
Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 2013;190:64-9.
Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, et al. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol 2014;66:1109-15.
Nravejsakul K, Na song-kha B, Raksakul W, Wongumpornwat T, Nuanthaisong U. Extended 14-core schematic diagram mapping prostate biopsy increases both the cancer detection rate and the accuracy of Gleason Score. Insight Urol 2020;41:75-80.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Insight Urology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
